Navigation Links
Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments
Date:11/1/2007

edical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancers.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. Health professionals or patients interested in clinical trials involving HGS products may inquire via the Contact Us section of the Company's web site, http://www.hgsi.com/products/request.html, or by calling us at (301) 610- 5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon, Albugon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, i
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Human Primary Preadipocytes and Differentiated Adipocytes
2. Low Abundance cDNA Cloned Using Stratagenes Human Universal cDNA Library
3. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Human Universal cDNA Library Array I
6. Map and Link Human Genetic Disorders with SSLP Analysis
7. RT-PCR Primer Sets for Human and Mouse Mismatch Repair Genes
8. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
9. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
10. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
11. Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression Vector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Donald Fresne, President and CEO ... Stephan Vagner , PhD to its Scientific Advisory Committee. ... Toulouse, France , performed research at Embl ... and at Inserm, the French institute of health and medical ... both at the Curie Institute, Orsay, France ...
(Date:9/16/2014)... TN (PRWEB) September 16, 2014 ... new initiatives to position themselves for their ... for labeling and encoding, Pharma Packaging Solutions ... new hardware and software and new procedures. ... current Good Manufacturing Practices (cGMP), Pharma Packaging ...
(Date:9/16/2014)... Denmark , Sept. 16, 2014  Ascendis ... innovative TransCon technology to address significant unmet medical ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  The full interim results will ... the GRS and IGF Society, being held October ...
(Date:9/16/2014)... 2014 RENU 28, the world's first and ... available for purchase in Australia and New Zealand in mid-August ... September 16th. The tour will make stops in Brisbane on ... the 18th, Sydney on the 20th, and Melbourne on the ... New Zealand and to educate people about the new product ...
Breaking Biology Technology:New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Wellness Company Hosts ASEA Australia Tour September 16-22 2
... OF INDUSTRY, Calif. and HONG KONG, June 30 EFT BioTech ... has successfully completed its inaugural Taiwan Strait passenger voyage which has ... the Taiwan Sun, and the Qatar Tribune. The article states: ... with China on Sunday, making it the first such cross-strait service ...
... Mass., June 30 Microfluidics, a wholly owned ... MFLU), and Particle Sciences Inc. (PSI) have formed ... the most advanced and reliable nanotechnology and formulation ... Pharmaceutical Ingredients (APIs). , , Particle Sciences ...
... from the Taichung Harbor to Xiamen , China ... , , CITY OF INDUSTRY, Calif. and HONG ... announced today that the Company,s subsidiary, Excalibur International Marine Corporation, completed ... 2009. The voyage across the Taiwan Strait takes only 4 ...
Cached Biology Technology:Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 2Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 3Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 2Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 3EFT BioTech Holdings, Inc.'s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 2EFT BioTech Holdings, Inc.'s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 3
(Date:9/16/2014)... Johns Hopkins neuroscientists have discovered the "molecular brakes" that ... ear cochleas of mice. These "hair cells" translate sound ... brain and are interpreted as sounds. If the arrangement ... , A summary of the research will be published ... 16. , "The proteins Hey1 and Hey2 act as ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
(Date:9/16/2014)... Hesperides vessel returned to Spain culminating the around the ... clear picture of how the global ocean works and ... pollutants from the atmosphere is not limited to coastal ... of the planet, and it is already affecting the ... week in CSIC Residence for Researchers in Barcelona, in ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... is on the rise and may be problematic, according ... the December issue of Obstetrics & Gynecology, Erin Tracy, ... and may present potential pitfalls for patients and physicians. ... have no proven clinical validity whatsoever and are quite ...
... for advanced age-related macular degeneration, researchers from Harvard and ... the cure. A research report published in the December ... endostatin to mice significantly reduced or eliminated abnormal blood ... the disease causes blindness. Our study provides ...
... brain injury and using club drugs have in common" ... chemical chain reaction in the brain, leading to cell death, ... series of studies at UF over the past five years ... MDMA, and other forms of methamphetamine lead to the same ...
Cached Biology News:Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2New treatment for age-related macular degeneration within sight 2Club drugs inflict damage similar to traumatic brain injury 2Club drugs inflict damage similar to traumatic brain injury 3
Request Info...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
... BUF040A is a diluent that is designed for ... which are paired with a mouse monoclonal coating ... rabbit and mouse proteins to prevent non-specific binding ... • This buffer may be used ...
Biology Products: